- Graduate School - University of Texas Health Science Center at Houston (2004-2006), Public Health
- Fellowship - UT Southwestern Medical Center (2002-2005), Endocrinology & Metabolism
- Internship/Residency - Texas Tech University Health Sciences Center (1999-2002), Internal Medicine
- Medical School - Carol Davila University of Medicine & Pharmacy (1992-1998)
- Graduate School - UT Southwestern Medical Center (2005-2008), Clinical Research
Ildiko Lingvay, M.D.
- Internal Medicine - Endocrinology
Ildiko Lingvay, M.D., M.P.H., M.S.C.S., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She holds a secondary appointment in the Department of Clinical Sciences.
Dr. Lingvay is an endocrinologist who specializes in clinical research in the fields of obesity, diabetes, and metabolic complications at UT Southwestern Medical Center. She treats patients with diabetes and thyroid cancer at UT Southwestern and Parkland Hospital.
Board certified in internal medicine, endocrinology, diabetes, and metabolism, she joined the UT Southwestern faculty in 2005.
Dr. Lingvay’s research interests include metabolic syndrome, obesity, and Type 2 diabetes mellitus. She has published scores of journal articles, book chapters, and case reports related to these conditions.
She serves on the editorial boards of several prominent journals, including Diabetes Care, Endocrine Practice, Journal of Investigative Medicine, and Diabetes and Vascular Disease Research.
Recognized with a number of honors and awards for her work as a researcher and mentor, Dr. Lingvay has delivered many invited lectures and meeting presentations in the U.S. and around the world.
Dr. Lingvay earned her medical degree at Carol Davila University of Medicine and Pharmacy in Romania. She completed an internal medicine residency at Texas Tech University Health Sciences Center and received advanced training in endocrinology and metabolism through a fellowship at UT Southwestern.
She also holds master’s degrees in public health and clinical sciences from UT Health Science Center at Houston and UT Southwestern, respectively.
Learn more about Dr. Lingvay’s publications and research efforts.
Meet Dr. Lingvay
Thyroid Cancer Specialist in Dallas
Endocrinologist Ildiko Lingvay, M.D., specializes in treating and coordinating the care of patients with thyroid cancer – helping deliver seamless, integrated care as part of UT Southwestern Medical Center’s multidisciplinary team of physicians who are experts in treating the disease.
“Thyroid cancer patients are referred to UT Southwestern because of our team’s expertise and experience, as well as our multidisciplinary approach,” Dr. Lingvay says.
“We have every treatment modality readily available to us, and, when necessary, we’re able to seamlessly coordinate comprehensive care with many different specialists.”
For instance, Dr. Lingvay and her team work closely with fellow UT Southwestern thyroid cancer specialists in endocrine surgery, medical oncology (Simmons Cancer Center), radiation oncology, radiology, and nuclear medicine.
The team also provides thyroid cancer patients with a nurse who serves as a contact point and care facilitator, regardless of which specialties patients need to see.
“Our patients really appreciate this because it helps them navigate the system and ensures that all the care they need is centralized and highly individualized,” Dr. Lingvay says.
Board certified and fellowship trained, Dr. Lingvay also treats patients with diabetes and other endocrine disorders at Parkland Hospital.
She is active in diabetes research, as well, and oversees a number of related clinical trials.
Dr. Lingvay says that one of the most gratifying parts of her work is the time she spends with patients.
“I enjoy interacting and developing relationships with our patients – seeing the joy in their eyes when I deliver good news and being able to help them when the news isn’t as good,” she says. “Because we treat a lot of people with chronic diseases, we tend to see them for many years.”
- The Endocrine Society
- European Association for the Study of Diabetes
- American Federation for Medical Research
- American Diabetes Association
- Jean W. Wilson Award for Scientific Mentorship 2011
Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options
Song L, McNulty JN, Lingvay I(Ed.) (2018), American Diabetes Association
Textbook of Endocrine Physiology
Lingvay I, Holt S(Ed.) (2012), Oxford University Press Inc
Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management
Lingvay I, Rhee C, Raskin P(Ed.) (2006)
Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide
Alexanian S, Lingvay I(Ed.) (2016), American Diabetes Association
Therapy for Diabetes Mellitus and Related Disorders
Lingvay I, Aviles-Santa LM, Raskin P(Ed.) (2009), American Diabetes Association
American College of Physicians- Medicine
Lingvay I, Raskin P(Ed.) (2006), American College of Physicians
- Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options
Random Blood Glucose: A Robust Risk Factor For Type 2 Diabetes.
Bowen ME, Xuan L, Lingvay I, Halm EA The Journal of clinical endocrinology and metabolism 2015 Feb jc20144116
Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy.
Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, Helmark IC, Wijayasinghe N, Larsen M Diabetes, obesity & metabolism 2017 Nov
Hyposialylated IgG activates endothelial IgG receptor Fc?RIIB to promote obesity-induced insulin resistance.
Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, Ahmed M, Szalai AJ, Vongpatanasin W, Mattrey RF, Chen Q, Azadi P, Lingvay I, Botto M, Holland WL, Kohler JJ, Sirsi SR, Hoyt K, Shaul PW, Mineo C The Journal of clinical investigation 2017 Nov
Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
Lingvay I, Chao J, Dalal MR, Meneghini LF Diabetes technology & therapeutics 2017 May 19 5 315-322
IDegLira was effective across a range of dysglycaemia and BMI categories in the DUAL V randomized trial.
Lingvay I, Harris S, Jaeckel E, Chandarana K, Ranthe MF, Jódar E Diabetes, obesity & metabolism 2017 Jun
Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes.
Bowen ME, Xuan L, Lingvay I, Halm EA American journal of preventive medicine 2017 Feb
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR Diabetes care 2017 Dec
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used.
Norwood P, Chen R, Jaeckel E, Lingvay I, Jarlov H, Lehmann L, Heller S Diabetes, obesity & metabolism 2017 Apr
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB JAMA 2016 Mar 315 9 898-907
First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report.
Dao BD, Lingvay I, Sailors J, Landay M, Shapiro G Journal of investigative medicine high impact case reports 2015 Jul-Sep 3 3 2324709615603723
Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges.
Gore MO, McGuire DK, Lingvay I, Rosenstock J Current cardiology reports 2015 Jul 17 7 607
Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge.
Pillai AK, Silvers W, Christensen P, Riegel M, Adams-Huet B, Lingvay I, Sun X, Öz OK Journal of diabetes research 2015 2015 789359
Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial.
Harrison LB, Adams-Huet B, Li X, Raskin P, Lingvay I Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2014 Feb
The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?
Pop LM, Lingvay I Current diabetes reports 2017 Oct 17 12 124
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2017 Mar
The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin.
Pokala N, Adams-Huet B, Li X, Harrison LB, Vanderheiden A, Lingvay I Diabetes, obesity & metabolism 2017 Jun
Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Vanderheiden A, Harrison L, Warshauer J, Li X, Adams-Huet B, Lingvay I JAMA internal medicine 2016 Jun
State of the Art: Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Anti-hyperglycemic Medications.
Alvarez CA, Lingvay I, Vuylsteke V, Koffarnus RL, McGuire DK Clinical pharmacology and therapeutics 2015 May
Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
Warshauer JT, Lopez X, Gordillo R, Hicks J, Holland WL, Anuwe E, Blankfard MB, Scherer PE, Lingvay I Diabetes/metabolism research and reviews 2015 May
Doc, I Just Ate: Interpreting Random Blood Glucose Values in Patients with Unknown Glycemic Status.
Bowen ME, Xuan L, Lingvay I, Halm EA Journal of general internal medicine 2017 Nov
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T The New England journal of medicine 2016 Sep
Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI.
Yokoo T, Clark HR, Pedrosa I, Yuan Q, Dimitrov I, Zhang Y, Lingvay I, Beg MS, Bobulescu IA Journal of magnetic resonance imaging : JMRI 2016 Mar
Mechanisms of Action of Liraglutide in Patients with Type 2 Diabetes Treated with High Dose Insulin.
Vanderheiden A, Harrison LB, Warshauer JT, Adams-Huet B, Li X, Yuan Q, Hulsey K, Dimitrov I, Yokoo T, Jaster AW, Pinho DF, Pedrosa I, Lenkinski RE, Pop LM, Lingvay I The Journal of clinical endocrinology and metabolism 2016 Feb jc20153906
Trends in thyroid cancer demographics and surgical therapy in the United States
Mitchell I, Livingston EH, Chang AY, Holt S, Snyder WH 3rd, Lingvay I, Nwariaku FE Surgery December 2007 142/6 823-8
Noninvasive quantification of pancreatic fat in humans
Lingvay I, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS The Journal of Clinical Endocrinology & Metabolism Fall 2009 94/10 4070-6
Pancreatic Steatosis - Harbinger of Type 2 Diabetes in Obese Rodents
Lee Y, Lingvay I, Szczepaniak LS, Orci L, Unger RH Internal Journal of Obesity Fall 2010 34/2 396-400
Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes
Zib I, Jacob AN, Lingvay I, Salinas K, McGavock JM, Raskin P, Szczepaniak LS Journal of Investigative Medicine July 2007 55/5 230-6
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P Diabetes Care October 2009 32/10 1789-95
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
Lingvay I, Leiter LA Circulation 2018 May 137 21 2200-2202
EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K, Liebl A Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018 Nov
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomised, controlled trial.
Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P The Journal of clinical endocrinology and metabolism 2018 Apr
When Metformin Is Not Enough: Pros and Cons of SGLT2 and DPP-4 Inhibitors as a Second Line Therapy.
Avogaro A, Delgado E, Lingvay I Diabetes/metabolism research and reviews 2018 Jan
Metabolic response 4 years after gastric bypass in a complete cohort with type 2 diabetes mellitus.
Gisella Carranza-Leon B, Puzziferri N, Adams-Huet B, Jabbour I, Lingvay I Diabetes research and clinical practice 2018 Jan
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR Diabetes care 2018 Jul
Roux-en-Y Gastric Bypass Compared to Equivalent Diet Restriction: Mechanistic Insights into Diabetes Remission.
Pop LM, Mari A, Zhao TJ, Mitchell L, Burgess S, Li X, Adams-Huet B, Lingvay I Diabetes, obesity & metabolism 2018 Mar
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A The lancet. Diabetes & endocrinology 2018 Jan
- Random Blood Glucose: A Robust Risk Factor For Type 2 Diabetes.
- Type 2 Diabetes Mellitus
- Metabolic Syndrome